A biotechnology company developing a machine learning-driven thymic cell engineering platform to restore normal immune function in aging and disease, the cutting-edge approach in iPSC-thymic cell manufacturing utilized by Thymmune Therapeutics Inc management and personnel can generate off-the-shelf cells at scale. The company approach is to develop a pipeline of therapies to treat immunodeficiencies, transplant related, and autoimmune diseases.
